FinasterideThird Party Manufacturing in India

Finasteride works as a competitive and specific inhibitor of the type II 5-alpha-reductase enzyme, a nuclear-bound steroid intracellular enzyme that converts testosterone into the more potent metabolite dihydrotestosterone (DHT). By blocking this conversion, finasteride significantly reduces serum DHT levels by approximately 70% and prostatic DHT levels by up to 90%. Since DHT is the primary androgen responsible for prostate growth and plays a key role in androgenetic alopecia, lowering its concentration produces therapeutic benefits for both conditions. Hair follicles contain type II 5-alpha-reductase, and in men with male pattern hair loss, the balding scalp shows elevated DHT levels. Finasteride decreases both scalp and serum DHT, inhibiting the process that leads to miniaturization of scalp hair follicles and potentially reversing the balding process. Unlike antiandrogens such as dutasteride which inhibits all three isoforms of 5-alpha-reductase, finasteride selectively targets the type II isoenzyme and has no affinity for the androgen receptor. It does not exhibit androgenic, antiandrogenic, estrogenic, or progestational effects. The drug is rapidly absorbed with approximately 65% bioavailability, is extensively metabolized in the liver via CYP3A4, and has a serum half-life of 5 to 6 hours. Upon discontinuation of therapy, DHT levels return to normal within 14 days.

Therapeutic Uses

Finasteride is prescribed for the treatment of:

• Benign Prostatic Hyperplasia (BPH): Reduces prostate volume and improves urinary flow in men with symptomatic enlarged prostate. Long-term use decreases the risk of acute urinary retention and delays the need for surgical intervention.
• Androgenetic Alopecia (Male Pattern Hair Loss): Slows hair thinning and promotes hair regrowth in men with mild to moderate male pattern baldness. Clinical effects become visible after 3 to 6 months of continuous therapy.
• Hirsutism (Off-label): Used to manage excessive hair growth in premenopausal women with hyperandrogenism, including those with polycystic ovary syndrome.

Why Manufacturers Choose Finasteride

Finasteride enjoys robust demand due to its established position in both urology and dermatology markets. BPH affects a significant portion of the aging male population worldwide, while androgenetic alopecia is one of the most common cosmetic concerns among men, creating dual high-volume revenue streams. The molecule is manufactured in two distinct strengths offering twice the market reach. Its production process is well-standardized, cost-efficient, and suitable for large-scale third-party manufacturing operations.

This makes Finasteride one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators, urology-focused product lines, dermatology portfolios, and export-oriented pharma companies.